Your browser doesn't support javascript.
loading
Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.
Diana, Giovanni; Strollo, Rocky; Diana, Davide; Strollo, Mirko; Galassi, Alfredo R; Crea, Filippo.
Affiliation
  • Diana G; Department of Cardiovascular Science, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Strollo R; Department of Medicine, Unit of Endocrinology & Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Diana D; Department of PROMISE, University of Palermo, Palermo, Italy.
  • Strollo M; Department of Veterinary Medicine and Animal Productions, Università Federico II, Naples, Italy.
  • Galassi AR; Department of PROMISE, University of Palermo, Palermo, Italy.
  • Crea F; Department of Cardiovascular Science, Università Cattolica del Sacro Cuore, Rome, Italy.
Eur Heart J Cardiovasc Pharmacother ; 7(3): e53-e54, 2021 05 23.
Article in En | MEDLINE | ID: mdl-32379302
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Drug Treatment / Minocycline / Anti-Bacterial Agents Limits: Humans Language: En Journal: Eur Heart J Cardiovasc Pharmacother Year: 2021 Type: Article Affiliation country: Italy
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Drug Treatment / Minocycline / Anti-Bacterial Agents Limits: Humans Language: En Journal: Eur Heart J Cardiovasc Pharmacother Year: 2021 Type: Article Affiliation country: Italy